Health and Healthcare

Merck : MRK

All Merck Articles

1087 Articles

Chris Lange | Apr 25, 2018 at 8:35 AM EDT

Short Sellers Grow More Selective on Major Pharma Stocks

The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected…

Jon C. Ogg | Apr 23, 2018 at 9:05 AM EDT

Top Analyst Upgrades and Downgrades: Amazon, Caterpillar, Exxon, Honeywell, Lululemon, Merck, Petrobras, Under Armour and More

The top analyst upgrades, downgrades and other research calls from Monday include Amazon.com, Caterpillar, Exxon Mobil, Honeywell, Lululemon Athletica, Merck,…

Jon C. Ogg | Apr 17, 2018 at 8:55 AM EDT

Top Analyst Upgrades and Downgrades: Bristol-Myers, Chesapeake Energy, Coca-Cola, Dropbox, GrubHub, Merck, Netflix, Twitter and More

The top analyst upgrades, downgrades and other research calls from Tuesday include Bristol-Myers Squibb, Chesapeake Energy, Coca-Cola, Dropbox, GrubHub, Merck,…

Jon C. Ogg | Apr 17, 2018 at 7:40 AM EDT

Merck Wins Big Against Rivals in Lung Cancer Study Survival Rates

Lung cancer may have just met a new standard of care. On top of that, it would be considered a new…

Paul Ausick | Apr 16, 2018 at 4:01 PM EDT

UnitedHealth, Merck Lift the Dow Monday

UnitedHealth, Merck, Verizon, and Caterpillar led the Dow to a nice gain Monday.

Chris Lange | Apr 11, 2018 at 8:30 AM EDT

The Major Pharma Stocks That Are Making Short Sellers Sick

The March 29 short interest data have been compared with the previous figures, and short interest in most of these…

Paul Ausick | Apr 9, 2018 at 4:01 PM EDT

Merck Intel Keep Dow in the Green Monday

Merck, Intel, JPMorgan Chase, and IBM led the Dow to a gain on Monday.

Chris Lange | Apr 9, 2018 at 10:05 AM EDT

Merck Moves Ahead With Late-Stage Trial Win

Shares of Merck had a boost early Monday after the firm announced that its Phase 3 trial of Keytruda for…

Chris Lange | Apr 6, 2018 at 10:05 AM EDT

What Has Tanked Incyte and NewLink Genetics

Incyte saw its shares make a sharp left turn on Friday after the firm gave an update on its late-stage…

Chris Lange | Mar 31, 2018 at 8:40 AM EDT

Major Biopharma Catalysts, Conferences and Decisions to Watch For in April

Here is a 24/7 Wall St. calendar with a few of the biggest biotech and pharmaceutical companies expecting clinical trial…

Paul Ausick | Mar 28, 2018 at 4:01 PM EDT

Merck, Walmart Buoy the Dow Wednesday

Merck and Walmart were among Wednesday's biggest gainers on the Dow while Intel and Cisco were among the big losers.

Chris Lange | Mar 27, 2018 at 8:45 AM EDT

Which Major Pharma Stocks Short Sellers Are Keen On

The March 15 short interest data have been compared with the previous figures, and short interest moves in these selected…

Lee Jackson | Mar 26, 2018 at 8:25 AM EDT

10 Stocks to Buy Now in Case 2019 Bear Market Does Come

The Stifel view is that it is time for investors to take a more defensive posture, but that doesn’t mean…

Chris Lange | Mar 12, 2018 at 8:35 AM EDT

Major Pharma Sees Big Drop in Short Interest

The February 28 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Feb 28, 2018 at 9:10 AM EST

Short Sellers Hike Bets in Major Pharma

The February 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical…

1 … 23 24 25 26 27 … 73

Merck : MRK

All Merck Articles

Short Sellers Grow More Selective on Major Pharma Stocks

Top Analyst Upgrades and Downgrades: Amazon, Caterpillar, Exxon, Honeywell, Lululemon, Merck, Petrobras, Under Armour and More

Top Analyst Upgrades and Downgrades: Bristol-Myers, Chesapeake Energy, Coca-Cola, Dropbox, GrubHub, Merck, Netflix, Twitter and More

Merck Wins Big Against Rivals in Lung Cancer Study Survival Rates

UnitedHealth, Merck Lift the Dow Monday

The Major Pharma Stocks That Are Making Short Sellers Sick

Merck Intel Keep Dow in the Green Monday

Merck Moves Ahead With Late-Stage Trial Win

What Has Tanked Incyte and NewLink Genetics

Major Biopharma Catalysts, Conferences and Decisions to Watch For in April

Merck, Walmart Buoy the Dow Wednesday

Which Major Pharma Stocks Short Sellers Are Keen On

10 Stocks to Buy Now in Case 2019 Bear Market Does Come

Major Pharma Sees Big Drop in Short Interest

Short Sellers Hike Bets in Major Pharma

QQQI Yields You Almost 14%, but Can It Survive a Dot-Com-Style Recession?

XOP vs. OIH: Do Drillers or Service Providers Best Ride Crude Above $100?

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

America's Debt Just Crossed a Level It Hasn't Hit Since 1946, and Households Are Next in Line

QQQI Yields You Almost 14%, but Can It Survive a Dot-Com-Style Recession?

XOP vs. OIH: Do Drillers or Service Providers Best Ride Crude Above $100?

Merck : MRK

All Merck Articles

Short Sellers Grow More Selective on Major Pharma Stocks

Top Analyst Upgrades and Downgrades: Amazon, Caterpillar, Exxon, Honeywell, Lululemon, Merck, Petrobras, Under Armour and More

Top Analyst Upgrades and Downgrades: Bristol-Myers, Chesapeake Energy, Coca-Cola, Dropbox, GrubHub, Merck, Netflix, Twitter and More

Merck Wins Big Against Rivals in Lung Cancer Study Survival Rates

UnitedHealth, Merck Lift the Dow Monday

The Major Pharma Stocks That Are Making Short Sellers Sick

Merck Intel Keep Dow in the Green Monday

Merck Moves Ahead With Late-Stage Trial Win

What Has Tanked Incyte and NewLink Genetics

Major Biopharma Catalysts, Conferences and Decisions to Watch For in April

Merck, Walmart Buoy the Dow Wednesday

Which Major Pharma Stocks Short Sellers Are Keen On

10 Stocks to Buy Now in Case 2019 Bear Market Does Come

Major Pharma Sees Big Drop in Short Interest

Short Sellers Hike Bets in Major Pharma

QQQI Yields You Almost 14%, but Can It Survive a Dot-Com-Style Recession?

XOP vs. OIH: Do Drillers or Service Providers Best Ride Crude Above $100?

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

Featured Reads

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

America's Debt Just Crossed a Level It Hasn't Hit Since 1946, and Households Are Next in Line